FLURANDRENOLIDE

Clinical safety rating: caution

Comprehensive clinical and safety monograph for FLURANDRENOLIDE (FLURANDRENOLIDE).

How it works

Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects.

What the body does with it

Metabolism	Primarily hepatic via CYP3A4; metabolites are inactive or weakly active.
Excretion	Renal (<1% unchanged), biliary/fecal (major route, as metabolites); <1% excreted unchanged in urine.
Half-life	Terminal elimination half-life approximately 18–36 hours; clinical context: prolonged with hepatic impairment; supports once-daily or twice-daily topical dosing.
Protein binding	Approximately 90% bound to plasma proteins, primarily to albumin and corticosteroid-binding globulin (CBG; transcortin).
Volume of Distribution	Vd estimated at 0.5–1.0 L/kg; clinical meaning: indicates moderate tissue distribution, not extensively sequestered.
Bioavailability	Topical: bioavailability is variable (1–10% systemically absorbed through intact skin; higher with occlusion, damaged skin, or prolonged use). Oral: not applicable; not administered systemically.
Onset of Action	Topical: onset of anti-inflammatory effect within 12–24 hours; occlusive dressing may enhance penetration and reduce onset time.
Duration of Action	Topical: duration of action up to 12–24 hours per application; clinical notes: frequency depends on severity; occlusion prolongs effect.

Classification & Brands

Dosing & administration

Apply 0.025% to 0.05% cream or ointment topically to affected area twice daily.

Dosage form	CREAM
Renal impairment	No dose adjustment required for topical use; systemic absorption minimal.
Liver impairment	No dose adjustment required for topical use; systemic absorption minimal.
Pediatric use	Apply sparingly to affected area once or twice daily; limit treatment duration and avoid occlusion due to increased systemic absorption risk.
Geriatric use	Use lowest effective dose for shortest duration; skin atrophy risk increased with prolonged use.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for FLURANDRENOLIDE (FLURANDRENOLIDE).

Breastfeeding

Topical flurandrenolide is minimally absorbed systemically; M/P ratio unknown. Use with caution on small areas for short duration. Avoid application to breast area or large denuded skin. Prefer lower potency agents if prolonged treatment needed.

Teratogenic Risk

Topical corticosteroids are generally considered low risk for teratogenicity when used as directed. However, high potency formulations or prolonged use over large areas may increase systemic absorption and potential risk. Flurandrenolide is a medium potency corticosteroid. Animal studies showed cleft palate and growth retardation at high doses. Human data are limited; avoid high doses and extensive areas during first trimester.

Warnings & precautions

■ FDA Black Box Warning

None.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to flurandrenolide or any component of the formulation","Untreated bacterial, fungal, viral, or parasitic skin infections","Vaccinia, varicella, or herpes simplex infections"]

Clinical Precautions

Precautions

["Systemic absorption may cause reversible HPA axis suppression, Cushing's syndrome, hyperglycemia, and unmask latent diabetes.","Local irritation, allergic contact dermatitis, and skin atrophy may occur.","Avoid prolonged use on face, intertriginous areas, or under occlusive dressings.","Use with caution in patients with skin infections or impaired circulation."]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

FLURANDRENOLIDE

Clinical safety rating: caution

Comprehensive clinical and safety monograph for FLURANDRENOLIDE (FLURANDRENOLIDE).

How it works

Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects.

What the body does with it

Metabolism	Primarily hepatic via CYP3A4; metabolites are inactive or weakly active.
Excretion	Renal (<1% unchanged), biliary/fecal (major route, as metabolites); <1% excreted unchanged in urine.
Half-life	Terminal elimination half-life approximately 18–36 hours; clinical context: prolonged with hepatic impairment; supports once-daily or twice-daily topical dosing.
Protein binding	Approximately 90% bound to plasma proteins, primarily to albumin and corticosteroid-binding globulin (CBG; transcortin).
Volume of Distribution	Vd estimated at 0.5–1.0 L/kg; clinical meaning: indicates moderate tissue distribution, not extensively sequestered.
Bioavailability	Topical: bioavailability is variable (1–10% systemically absorbed through intact skin; higher with occlusion, damaged skin, or prolonged use). Oral: not applicable; not administered systemically.
Onset of Action	Topical: onset of anti-inflammatory effect within 12–24 hours; occlusive dressing may enhance penetration and reduce onset time.
Duration of Action	Topical: duration of action up to 12–24 hours per application; clinical notes: frequency depends on severity; occlusion prolongs effect.

Classification & Brands

Dosing & administration

Apply 0.025% to 0.05% cream or ointment topically to affected area twice daily.

Dosage form	CREAM
Renal impairment	No dose adjustment required for topical use; systemic absorption minimal.
Liver impairment	No dose adjustment required for topical use; systemic absorption minimal.
Pediatric use	Apply sparingly to affected area once or twice daily; limit treatment duration and avoid occlusion due to increased systemic absorption risk.
Geriatric use	Use lowest effective dose for shortest duration; skin atrophy risk increased with prolonged use.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for FLURANDRENOLIDE (FLURANDRENOLIDE).

Breastfeeding

Teratogenic Risk

Warnings & precautions

■ FDA Black Box Warning

None.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to flurandrenolide or any component of the formulation","Untreated bacterial, fungal, viral, or parasitic skin infections","Vaccinia, varicella, or herpes simplex infections"]